Synaptogenix Inc (SNPX)

[bellweather1]

Well, because AXSM went up approximately 10x after it's MDD Ph2 results(and has a lot further to go, but that's another story), many have suggested that we should expect much the same thing if successful. But that may be too conservative, because, although there are a number of depression drugs(though they're admittedly underwhelming, due to side effects and questionable efficacy), they do work at some reasonable level. And even when they don't, there are alternatives(cognitive therapy, etc.). So AXSM's drug was/will be a significant improvement on what's already available.

But there are no real drugs for AD, and unlike depression, AD is ultimately a life threatening condition in practically all cases. Therefore, the need is much greater and the consequences of no available medications are, by and large, much more severe.

So, I think if the results are really good(comparable to the previous ones), the market cap may possibly go up twice as much...a billion MC over 3-6 months?, for starters. Of course, one big Q mark is, will an oral version be easily and quickly forthcoming?